In addition, the inhibitor did not modify surface CCR7 expression profiles in T-cells from CLL patients on treatment with ibrutinib, nor in patients who had developed refractory/relapsed disease to the drug. Here, CCR7 is linked to B-cell chronic lymphocytic leukemia.